| [1] |
Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008[J]. Ann Oncol, 2011, 22(12): 2675–2686.
|
| [2] |
Yang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost[J]. Int J Cancer, 2004, 109(3): 418–424.
|
| [3] |
World Health Organization. Draft action plan for the prevention and control of noncommunicable diseases 2013-2020[R]. Geneva: WHO, 2013: 1–36.
|
| [4] |
Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012[R]．[2015-02-02]．
URL
|
| [5] |
陈万青，赵平，乔友林，等. 2004－2005年全国第三次死因回顾抽样调查方法介绍[J]. 中华预防医学杂志，2010, 44(5)：303–309.
|
| [6] |
陈万青，郑荣寿，曾红梅，等. 1989－2008年中国恶性肿瘤发病趋势分析[J]. 中华肿瘤杂志，2012, 34(7): 517–524.
|
| [7] |
曾红梅，郑荣寿，张思维，等. 1989－2008年中国恶性肿瘤死亡趋势分析[J]. 中华肿瘤杂志，2012, 34(7): 525–532.
|
| [8] |
胡尚英，郑荣寿，赵方辉，等. 1989至2008年中国女性子宫颈癌发病和死亡趋势分析[J]. 中国医学科学院学报，2014, 36(2): 119–125.
|
| [9] |
应倩，夏庆民，郑荣寿，等. 中国2009年宫颈癌发病与死亡分析[J]. 中国肿瘤，2013, 22(8): 612–616.
|
| [10] |
赫捷，赵平，陈万青. 2012中国肿瘤登记年报[M]. 北京：军事医学科学出版社，2012：33–38.
|
| [11] |
Fan Jin, Susan S, Devesa WC, et al. Cancer incidence trends in urban Shanghai, 1972-1994: an update[J]. Int J Cancer, 1999, 83(4): 435–440.
|
| [12] |
乔友林，张林琦. 人乳头瘤病毒引起子宫颈癌机理和人免疫缺陷病毒的发现-2008年诺贝尔生理学/医学奖评述．中国科学院2009科学发展报告[M]. 北京：科学出版社，2009: 112–119.
|
| [13] |
Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer[J]. J Clin Pathol, 2002, 55(4): 244–265.
|
| [14] |
Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasivecervical cancer and high-grade cervical lesions: a meta-analysisupdate[J]. Int J Cancer, 2007, 121(3)：621–632.
|
| [15] |
Tjalma WA, Fiander A, Reich O, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe[J]. Int J Cancer, 2013, 132(4): 854–867.
|
| [16] |
Chen W, Zhang X, Molijn A, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV-16 and -18[J]. Cancer Causes Control, 2009, 20(9)：1705–1713.
|
| [17] |
Kimbauer R, Booy F, Cheng N, et al. Papilomavirus L1 major capsid protein self-assemble into virus-like particles that are highly immunogemic[J]. Proc Natl Acad Sci USA, 1992, 89(24)：12180–12184.
|
| [18] |
Stanley M. HPV - immune response to infection and vaccination[J]. Infect Agent Cancer, 2010, 5(19)：1–6.
|
| [19] |
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases[J]. N Engl J Med, 2007, 356(19)：1928–1943.
|
| [20] |
Future Ⅱ Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J]. N Engl J Med, 2007, 356(19)：1915–1927.
|
| [21] |
Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase Ⅲ double-blind, randomised controlled trial[J]. Lancet, 2007, 369(9580): 2161–2170.
|
| [22] |
Miltz A, Price H, Shahmanesh M, et al. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure[J]. PLoS One, 2014, 9(3): e90348.
|
| [23] |
Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials[J]. Vaccine，2006，24 (Suppl 3): 114–121.
|
| [24] |
Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects[J]. Vaccine, 2013, 31(37): 3811–3817.
|
| [25] |
Joura E, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. N Engl J Med, 2015, 372(8): 711–723.
|
| [26] |
Kirby T. FDA approves new upgraded Gardasil 9[J]. Lancet Oncol，2015, 16(2)：e56.
|
| [27] |
WHO Report. Human papillomavirus vaccines: WHO position paper, October 2014：recommendations[J]. Vaccine, 2014, 37(5): 338–344.
|
| [28] |
Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden[J]. J Natl Cancer Inst, 2008, 100(9)：622–629.
|
| [29] |
Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial[J]. Lancet, 2007, 370(9585): 398–406.
|
| [30] |
Sauvaget C, Fayette JM, Muwonge R, et al. Accuracy of visual inspection with acetic acid for cervical cancer screening[J]. Int J Gynaecol Obstet, 2011, 113(1)：14–24.
|
| [31] |
Sankaranarayanan R, Basu P, Wesley RS, et al. Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa[J]. Int J Cancer, 2004, 110(6): 907–913.
|
| [32] |
赵方辉，章文华，潘秦镜，等. 宫颈癌多种筛查方案的研究[J]. 中华肿瘤杂志，2010，32(6)：420–424.
|
| [33] |
Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials[J]. Lancet, 2014, 383(9916): 524–532.
|
| [34] |
Ogilvie GS, Krajden M, van Niekerk DJ, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial - the HPV focal study[J]. British J Cancer, 2012, 107(12): 1917–1924.
|
| [35] |
Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of Current American Cancer Society Guidelines and Current Issues in Cancer Screening[J]. CA Cancer J Clin, 2015, 65(1)：30–54.
|
| [36] |
Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China[J]. Lancet Oncol, 2008, 9(10): 929–936.
|
| [37] |
Abraham J, Stenger M. Cobas HPV test for first-line screening for cervical cancer[J]. J Community Support Oncol, 2014, 12(5): 156–157.
|
| [38] |
Castle PE, Stoler MH, Wright TC, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV-16 or HPV-18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study[J]. Lancet Oncol, 2011，12(9): 880–890.
|
| [39] |
Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance[J]. Gynecol Oncol, 2015, 136(2)：178–182.
|